fashion -WSS

fashion

author：knowledge 2025-10-02 11:38:11 - browse：258

Immunofluorescence image shows CD4+ (green) and CD8+ (yellow) T cells in the microenvironment of a head and neck squamous cell carcinoma. — This immunofluorescence image shows T cells (in green and yellow) in the microenvironment of a head and neck squamous cell carcinoma. Allen Lab/NCI/NIH

Merus said Tuesday that the combination of its experimental drug petosemtamab with the checkpoint inhibitor Keytruda shrank tumors in 62% of patients with head and neck cancer, according to an interim analysis of an ongoing mid-stage clinical trial.

The new efficacy results, derived from a larger number of patients, look similar to an initial disclosure made last week that triggered a 36% increase in Merus’ stock price.

But the Dutch drugmaker on Tuesday withheld additional information from the study related to the safety and durability of petosemtamab’s tumor responses, pending presentation at the annual meeting of the American Society of Clinical Oncology on June 3.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： In Memoriam: Notable people who died in 2023
Next article： Severe heat forecast: Where scorching temperatures will persist over the next week

knowledge

focus

WSS

Clinic falsely told dozens they had Alzheimer's, suits say

Medicare to cover more brain scans for Alzheimer’s patients

A public scorecard can help hold safety

Biden tests positive for Covid

'The Earth is screaming at us': Gov. Inslee calls for climate action amid record heat

Medicare to cover more brain scans for Alzheimer’s patients

focus

fashion

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

explore

Novavax promises a turnaround & Lilly roils the obesity market

FDA approves RSV monoclonal antibody for infants, toddlers

At least 13 dead in Texas as scorching temps continue

Sanders adds drug shortage policies to pandemic preparedness bill

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Weekend shootings leave at least 6 dead, 20 others wounded in Chicago

Walensky prepares to leave CDC — and Congress — behind

Listen: Wegovy in the brain & pivotal Alzheimer's data

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

How dance can help nurses traumatized by Covid

Wikipedia

'The Earth is screaming at us': Gov. Inslee calls for climate action amid record heat

Startup Neumora takes a novel depression drug to Phase 3

FDA moves to stop vape shops from selling Elf Bar, Esco Bars

Sanders adds drug shortage policies to pandemic preparedness bill

Novartis develops a rapidly manufactured CAR

Whistleblower: Blue Cross Blue Shield evaded $170 million in taxes

knowledge

focus

knowledge

hotspot